A61K 39/04
Mycobacterium
Official title: Mycobacterium, e.g. Mycobacterium tuberculosis
A61K39/04 (Mycobacterium) appears on 614 US grants and 895 published applications in this corpus.
Search patents in A61K- Granted patents
- 614
- Published applications
- 895
- Assignees
- 454
- Inventors
- 1,405
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 9 | 0 |
| 1999 | 9 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 2 |
| 2002 | 15 | 19 |
| 2003 | 8 | 20 |
| 2004 | 4 | 28 |
| 2005 | 7 | 13 |
| 2006 | 11 | 24 |
| 2007 | 5 | 25 |
| 2008 | 7 | 26 |
| 2009 | 15 | 34 |
| 2010 | 20 | 34 |
| 2011 | 29 | 43 |
| 2012 | 30 | 38 |
| 2013 | 25 | 50 |
| 2014 | 26 | 51 |
| 2015 | 33 | 51 |
| 2016 | 30 | 40 |
| 2017 | 42 | 49 |
| 2018 | 37 | 42 |
| 2019 | 39 | 36 |
| 2020 | 33 | 41 |
| 2021 | 27 | 46 |
| 2022 | 23 | 43 |
| 2023 | 27 | 41 |
| 2024 | 29 | 38 |
| 2025 | 28 | 35 |
| 2026 | 10 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Construction method of recombinant drug-resistant Mycobacterium bovis bacillus calmette-guerin (BCG) strain and pharmaceutical composition for treating tuberculosis (TB)30 Jun 2026US 12,667,608 B2Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- BCG based vaccine compositions and methods of use thereof23 Jun 2026US 12,661,393 B2The Johns Hopkins University
- Recombinant BCG, preparation method therefor and application thereof9 Jun 2026US 12,648,989 B2Xuzhou Hairun Biotechnology Co., Ltd.
- Vaccine composition for preventing tuberculosis comprising chorismate mutase26 May 2026US 12,636,357 B2Seoul National University R&Db Foundation
- Live self-destructing bacterial adjuvants to enhance induction of immunity19 May 2026US 12,629,417 B2University of Florida Research Foundation, Inc.
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Rna for preventing or treating tuberculosis24 Sep 2026US 2026/0284168 A1
- Compositions and methods for preventing, controlling and diagnosing mycobacterial infections17 Sep 2026US 2026/0273038 A1University of Saskatchewan
Most cited
By later US patents
- Method for muscle delivery of drugs, nucleic acids and other compounds166US 6,958,060 B2Genetronics, Inc. · 2005
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995
- Avirulent microbes and uses therefor: salmonella typhi103US 5,294,441 AWashington University · 1994
- Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells90US 6,261,281 B1Electrofect AS · 2001
- Method for genetic immunization85US 6,610,044 B2Inovio AS · 2003